Strategic Planning & ConsultingProvide strategic guidance and advice to the Board and executive team, leveraging extensive pharmaceutical industry expertise and leadership experience.Contribute to the company's growth and success by sharing insights on market trends, regulatory developments, emerging technologies, and the competitive landscape.Provide high-level strategic guidance and advice to the Board and executive team on matters related to drug development, manufacturing, and commercialization.Share deep industry knowledge and insights to inform strategic decisions, including product development, market expansion, and business partnerships.Provide expert perspectives on regulatory compliance, quality assurance, and risk management strategies.Assist in developing and evaluating long-term business plans and goals.Corporate Governance:Participate in Board committee meetings and provide valuable input on key corporate governance matters.Ensure that the Board and executive team comply with all relevant laws, regulations, and corporate policies.Maintain the highest standards of corporate governance and promote transparency and accountability.Advisory & Communication:Serve as a trusted advisor to the CEO and senior management team, promoting open communication and collaboration.Assist the President in communicating with internal and external stakeholders, including investors, analysts, government officials, and the media.Prepare speeches and presentations, and speak on behalf of the company at industry events and conferences.

Responsible for formulating the company's business plans and goals and coordinating work among various departments. Develop your own work goals and work plans, and conscientiously complete your respective tasks in accordance with the company's requirementsSkill introduction: From 2015 to 2021, Sanofi Group released a number of innovative drugs, providing patients with new treatment options.2015Tofacitinib: A JAK inhibitor used to treat conditions such as rheumatoid arthritis, ankylosing spondylitis, and Crohn's disease.Ocrelizumab: A B-cell selective apoptotic agent used to treat multiple sclerosis.2016Adalimumab: A TNF-alpha inhibitor used to treat conditions such as rheumatoid arthritis, ankylosing spondylitis, and Crohn's disease.Eculizumab: A C5 complement inhibitor used to treat hereditary angioedema.2017Alogliptin: A DPP-4 inhibitor used to treat diabetes.Voglitazone: A PPARγ agonist used to treat diabetes.2018Olaparib: A PARP inhibitor used to treat BRCA-mutated ovarian cancer, breast cancer and other diseases.Dacomitinib (Dapagliflozin): An SGLT-2 inhibitor used to treat diabetes.2019Alogliptin/Voglitazone: A DPP-4 inhibitor/PPARγ agonist combination used to treat diabetes.Dapagliflozin/Empagliflozin: A combination SGLT-2 inhibitor/SGLT-1 inhibitor used to treat diabetes.2020Sorafenib: A multi-target tyrosine kinase inhibitor used to treat hepatocellular carcinoma, renal cell carcinoma and other diseases.Cagliptin: A DPP-4 inhibitor used to treat diabetes.2021Setonacept: An IL-23p19 inhibitor used to treat conditions such as Crohn's disease and ankylosing spondylitis.Alogliptin/Cagliptin: A combination of DPP-4 inhibitors used to treat diabetes.These drugs have shown good efficacy and safety in clinical trials, providing patients with new treatment options. Sanofi Group will continue to be committed to developing innovative drugs to bring greater health benefits to patients.